Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up

Zenda, Sadamoto; Kawashima, Mitsuhiko; Arahira, Satoko; Kohno, Ryosuke; Nishio, Teiji; Tahara, Makoto; Hayashi, Ryuichi; Akimoto, Tetsuo

doi:10.1007/s10147-014-0737-8

Cited by 21 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53,57,65 A recent report from Japan described long-term toxicities after proton therapy in 90 patients with nasal cavity, paranasal sinus, or skull base malignancies. 52 Late toxicities reached grade 3 in 17 patients (19%) and grade 4 in 6 patients (7%) (encephalomyelitis infection in 2 patients, optic nerve disorder in 4 patients). This rate of grade 3 to 4 late toxicity with protons (19%) was similar to the rate reported for conventional RT with photons (16%).…”

Section: Particle Therapiesmentioning

confidence: 97%

“…25,43–45 Proton therapy has been used to treat oropharyngeal cancers, sinonasal malignancies, and mucosal melanomas, although the clinical data are best established for ocular melanomas and chordomas. 46–51 Single-institution outcome data have been reported for these H&N cancers, 43,47–49,52,53 but the literature does not easily allow direct comparisons between proton therapy and IMRT; historical comparisons warrant cautious interpretation, because improvements in diagnosis and staging evaluations may lead to improvements in reported outcomes independent of therapy. Mindful of these caveats, a recent systematic review and meta-analysis of noncomparative observation studies concluded that patients with malignant diseases of the nasal cavity and paranasal sinuses who received proton therapy seemed to have better outcomes than those receiving photon therapy.…”

Section: Particle Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Head and Neck Cancers, Version 1.2015

Pfister

Spencer

Brizel

et al. 2015

J Natl Compr Canc Netw

200

246

View full text Add to dashboard Cite

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

show abstract

Section: Particle Therapiesmentioning

confidence: 97%

Section: Particle Therapiesmentioning

confidence: 99%

Head and Neck Cancers, Version 1.2015

Pfister

Spencer

Brizel

et al. 2015

J Natl Compr Canc Netw

200

246

View full text Add to dashboard Cite

show abstract

“…The clinical data on proton therapy were first established with ocular malignant melanoma and chondroma. Since then, it has been mainly used for oropharyngeal carcinoma, sinonasal malignancy, and mucosal melanoma, and has contributed to organ preservation . Tokuuye et al treated head and neck malignancies in patients with no history of surgical resection with 250‐MeV protons with or without X‐ray irradiation.…”

Section: Particle Radiotherapy Using Proton and Carbon Ionsmentioning

confidence: 99%

“…In the toxicities observed after long‐term observation of 90 patients, grade 3 late toxicities occurred in 17 (19%) patients and grade 4 late toxicities in 6 (7%) patients. Late toxicity can still occur at 5 years after treatment …”

Section: Particle Radiotherapy Using Proton and Carbon Ionsmentioning

confidence: 99%

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Yura

Tada

Fujita

et al. 2019

Oral Science International

View full text Add to dashboard Cite

Malignant tumors such as squamous cell carcinoma (SCC), malignant salivary gland tumor, mucosal melanoma, sarcoma, and lymphoma occur in the oral cavity. Among them, oral SCC accounts for 90%. The frequency of lymph node metastasis of oral SCC varies depending on the site of occurrence, which affects the prognosis. Surgery is the primary treatment for oral cancer, but when the tumor extends, postoperative radiation with or without chemotherapy is required. Photons including X-rays and γ-rays are the most widely used types of ionizing radiation in cancer radiotherapy. Particle radiotherapy using protons and carbon ions shows a highly focused dose distribution to tumor tissues. Carbon ion therapy is effective for salivary gland tumors, malignant melanomas, and sarcomas which are less susceptible to photons. Furthermore, boron neutron capture therapy with tumor selectivity is expected to further reduce damage to surrounding normal cells. The introduction of novel radiotherapy to current treatment might improve the prognosis of patients and organ preservation. K E Y W O R D S chemotherapy, oral cancer, particle radiotherapy, radiotherapy, surgery How to cite this article: Yura Y, Tada S, Fujita Y, Hamada M. Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. Oral Sci Int. 2019;16:49-68. https://doi.

show abstract

“…The recommendations of the Director of the Medical Technology Assessment and Tariff Assessment Agency concerning adult cancer include chordoma and chondrosarcoma of the base of the skull and paraspinal region, paranasal sinus tumors and low-grade gliomas [28]. Supporting scientific evidence, similar to childhood cancers, is equally applicable for favourable irradiation efficacy as likewise are the significantly reduced adverse reactions [34][35][36][37][38]. It seems justified in this case to consider extending the indications to include other head and neck tumours near the base of the skull, thereby enabling the neighbouring and radiosensitive structures of the CNS and vasculature to be protected [39].…”

mentioning

confidence: 99%

Proton radiotherapy should be further developed in Poland

Maciejczyk¹,

Sztuder²

2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Proton radiation therapy needs to be further developed in Poland by virtue of both epidemiological considerations and because this type of radiation exhibits very advantageous biological and physical properties. The underlying benefit of such therapy is to make lower integral radiation dose delivered to structures beyond a given target area, including critical organs, resulting in reduced toxicities for patients. Of somewhat less import is the improvement in dose distributions for target areas (vs photons), which can potentially bring about a better local control. As a result, proton radiotherapy is mainly indicated for paediatric cases, where any development of complications is most likely because of the long lifetimes and the heightened radiosensitivity of healthy tissues. The most recent studies also show that certain subpopulations of patients can benefit from proton beam radiotherapy in cases of widespread cancers such as from the lung or breast. A further advantage is found after conducting a cost-effectiveness analysis whereby proton beam radiotherapy was demonstrated as a cost-effective procedure, with both lowered costs for treating complications and indirect costs. By the term 'development' as used herein, it is understood that there is a need to open another proton therapy centre in Poland; this question however being left open in the presented article. Nevertheless, before taking such a high-level decision, the following requires consideration: the working experience garnered by the existing Cyclotron Centre at Bronowice (CCB), outcomes from current prospective clinical trials and, above all, delivering appropriately managed and coordinated oncological care for cancer patients in Poland regarding multi-centre collaboration between specialists. NOWOTWORY J Oncol 2017; 67, 1: 65-70

show abstract

Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up

Abstract: In conclusion, the late toxicity profile of PBT in patients with malignancy involving the nasal cavity, para-nasal sinuses, or skull base malignancy was partly clarified. Because late toxicity can still occur at 5 years after treatment, long-term follow-up is necessary.

Cited by 21 publications

References 21 publications

Head and Neck Cancers, Version 1.2015

Head and Neck Cancers, Version 1.2015

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Proton radiotherapy should be further developed in Poland

Contact Info

Product

Resources

About